30.01
0.66%
-0.20
アフターアワーズ:
30.01
前日終値:
$30.21
開ける:
$30.39
24時間の取引高:
21,608
Relative Volume:
0.89
時価総額:
$355.72M
収益:
$9.71M
当期純損益:
$-29.96M
株価収益率:
-11.16
EPS:
-2.69
ネットキャッシュフロー:
$-14.79M
1週間 パフォーマンス:
-3.69%
1か月 パフォーマンス:
+2.07%
6か月 パフォーマンス:
+17.64%
1年 パフォーマンス:
+87.91%
Xoma Royalty Corp Stock (XOMA) Company Profile
XOMA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
XOMA | 30.01 | 355.72M | 9.71M | -29.96M | -14.79M | -2.69 |
VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2021-09-07 | ダウングレード | Wedbush | Outperform → Neutral |
2021-06-29 | 開始されました | Aegis Capital | Buy |
2021-01-19 | 繰り返されました | H.C. Wainwright | Buy |
2018-01-18 | 繰り返されました | H.C. Wainwright | Buy |
2017-10-17 | 再開されました | H.C. Wainwright | Buy |
2017-09-05 | アップグレード | Wedbush | Neutral → Outperform |
2017-06-12 | 開始されました | H.C. Wainwright | Buy |
2016-11-14 | ダウングレード | Wedbush | Outperform → Neutral |
2016-03-11 | 繰り返されました | Wedbush | Outperform |
2015-07-23 | ダウングレード | Jefferies | Buy → Hold |
2015-07-22 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
2015-07-22 | ダウングレード | Piper Jaffray | Overweight → Neutral |
2014-10-10 | 再開されました | ROTH Capital | Buy |
2014-04-29 | アップグレード | MLV & Co | Hold → Buy |
2014-03-11 | ダウングレード | MLV & Co | Buy → Hold |
2014-03-05 | 繰り返されました | Ladenburg Thalmann | Buy |
2013-10-31 | 繰り返されました | MLV & Co | Buy |
2013-05-09 | 繰り返されました | Ladenburg Thalmann | Buy |
2012-05-14 | 開始されました | Cowen & Co | Outperform |
2011-03-31 | 繰り返されました | MLV Capital | Buy |
2011-03-23 | 繰り返されました | RBC Capital Mkts | Outperform |
2011-01-06 | 繰り返されました | Ladenburg Thalmann | Buy |
2011-01-04 | 繰り返されました | Wedbush | Outperform |
すべてを表示
Xoma Royalty Corp (XOMA) 最新ニュース
Short Interest in XOMA Co. (NASDAQ:XOMA) Drops By 23.5% - Defense World
XOMA Co. (NASDAQ:XOMA) Sees Large Decrease in Short Interest - MarketBeat
Xoma royalty corp CFO Thomas Burns sells shares worth $292,663 By Investing.com - Investing.com Australia
Xoma CEO Owen Hughes sells $655,335 in stock - Investing.com India
Xoma royalty corp CFO Thomas Burns sells shares worth $292,663 - Investing.com
What Makes XOMA Royalty (XOMA) a New Buy Stock - Yahoo Finance
XOMA Royalty Reports Third Quarter 2024 Financial Results and Recent Activities - Defense World
What is HC Wainwright's Forecast for XOMA FY2025 Earnings? - MarketBeat
XOMA Royalty Corporation (NASDAQ:XOMA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
XOMA Royalty Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
XOMA Royalty’s Third Quarter 2024 Financial Insights - TipRanks
XOMA Royalty: Q3 Earnings Snapshot - CT Insider
XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities - ForexTV.com
Xoma reports Q3 EPS ($1.59), consensus (44c) - TipRanks
XOMA Royalty Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
XOMA Reports Mixed Q3: FDA Approval Win Despite $17.2M Loss, Expands Portfolio | XOMA Stock News - StockTitan
XOMA stock soars to 52-week high, reaching $32 By Investing.com - Investing.com UK
XOMA stock soars to 52-week high, reaching $32 - Investing.com
XOMA (NASDAQ:XOMA) Shares Cross Above Two Hundred Day Moving AverageHere's Why - MarketBeat
XOMA (NASDAQ:XOMA) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s Why - Defense World
XOMA Royalty Corporation's (NASDAQ:XOMA) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week - Simply Wall St
XOMA stock soars to 52-week high, reaching $30.7 By Investing.com - Investing.com South Africa
XOMA stock soars to 52-week high, reaching $30.7 - Investing.com India
XOMA’s (XOMA) Buy Rating Reaffirmed at HC Wainwright - Defense World
XOMA Co. (NASDAQ:XOMAO) Short Interest Down 40.0% in October - Defense World
Twist Bioscience enters into purchase agreement with XOMA Royalty - MSN
XOMA (NASDAQ:XOMA) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
XOMA Royalty Corporation Acquires 50% of Twist's Existing Royalty and Milestone Economics for $15 Million - Marketscreener.com
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience - The Manila Times
XOMA Royalty Significantly Expands its Royalty and - GlobeNewswire
Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash - The Bakersfield Californian
Investors in XOMA Royalty (NASDAQ:XOMA) have seen favorable returns of 72% over the past year - Yahoo Finance
Ellsworth Advisors LLC Makes New $516,000 Investment in XOMA Co. (NASDAQ:XOMA) - MarketBeat
XOMA stock soars to 52-week high, reaching $30.49 - Investing.com
XOMA stock soars to 52-week high, reaching $30.49 By Investing.com - Investing.com South Africa
XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties (NASDAQ:XOMA) - Seeking Alpha
XOMA (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
XOMA Co. (NASDAQ:XOMA) is Stonepine Capital Management LLC’s 6th Largest Position - Defense World
PIMCO Strategic Income Fund, XOMA Corporation, Another 2 Companies Have A High Estimated Dividend Yield - Via News Agency
Rhumbline Advisers Raises Stock Holdings in XOMA Co. (NASDAQ:XOMA) - Defense World
XOMA (NASDAQ:XOMA) Shares Pass Above 200-Day Moving Average of $25.91 - Defense World
XOMA (NASDAQ:XOMA) Stock Price Crosses Above Two Hundred Day Moving Average of $25.91 - MarketBeat
XOMA Co. (NASDAQ:XOMAO) Announces $0.52 Quarterly Dividend - Defense World
XOMA shares hold as analyst reiterates Buy rating post-FDA nod - Investing.com
XOMA Royalty gains FDA-approved asset for NPC By Investing.com - Investing.com Canada
XOMA Royalty gains FDA-approved asset for NPC - Investing.com
XOMAOXOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock Latest Stock News & Market Updates - StockTitan
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. - GlobeNewswire
Xoma notes FDA approval of Zevra’s MIPLYFFA in patients with NPC - TipRanks
Xoma Royalty Corp (XOMA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):